Trial reportJACC. Heart failure2014
Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study.
Trial report in JACC. Heart failure, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 85 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity.
Colchicine in Acutely Decompensated Heart Failure With Reduced Ejection Fraction: a Pilot Study
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
Who cites it
85 citing papers in PubMed, 4 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Pooled it
- A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease.Frontiers in cardiovascular medicine · 2021Pooled it
- Colchicine for prevention of cardiovascular events.The Cochrane database of systematic reviews · 2016Pooled it
- Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2015Pooled it
- Colchicine reduces inflammatory cytokines and improves symptoms in HFpEF: an observational pilot study.Frontiers in medicine · 2025Trial
- Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial.European journal of clinical pharmacology · 2024Trial
- Trial
- The Immunological Consequences of Clonal Hematopoiesis in Heart Failure.Immunological reviews · 2026Review
- Evaluating the risk of atrial fibrillation in patients with chronic recurrent pericarditis prescribed colchicine: Observations using TriNetX global federated research network.European journal of clinical pharmacology · 2025Observational
- Anti-inflammatory pharmacotherapy in patients with cardiovascular disease.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Targeting inflammation in heart failure: evolving insights and future directions from randomized clinical trials.Heart failure reviews · 2025Review
- Review
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.Journal of the American College of Cardiology · 2025Review
- The NO Pathway as a Target in Patients with Stable and Advanced Heart Failure: An Additional Arrow in Our Quiver!Biomolecules · 2025Review
- Immunometabolism in heart failure.Nature reviews. Cardiology · 2025Review
- High-sensitivity C-reactive protein and 6-month all-cause mortality in Chinese heart failure patients.Scientific reports · 2025Article
- Effects of colchicine on depression scale scores of patients with chronic heart failure with reduced ejection fraction: A randomized clinical trial.Journal of cardiovascular and thoracic research · 2025Article
- Myeloperoxidase inhibition in the landscape of anti-inflammatory therapies for heart failure with preserved ejection fraction: the ENDEAVOR trial.Heart failure reviews · 2025Review
- Colchicine therapy in cardiovascular medicine: A literature review.American heart journal plus : cardiology research and practice · 2025Review
- Gut microbiota-related modulation of immune mechanisms in post-infarction remodelling and heart failure.ESC heart failure · 2025Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of this study was to test the efficacy of a 6-month course of anti-inflammatory treatment with colchicine in improving functional status of patients with stable chronic heart failure (CHF).
backgroundCHF has been shown to be associated with inflammatory activation. Inflammation has been designated as a therapeutic target in CHF.
methodsPatients with stable CHF were randomly assigned to colchicine (0.5 mg twice daily) or placebo for 6 months. The primary endpoint was the proportion of patients achieving at least one-grade improvement in New York Heart Association class.
resultsTwo hundred sixty-seven patients were available for final evaluation of the primary endpoint: its rate was 11% in the control group and 14% in the colchicine group (odds ratio: 1.40; 95% confidence interval: 0.67 to 2.93; p = 0.365). The rate of the composite of death or hospital stay for heart failure was 9.4% in the control group, compared with 10.1% in the colchicine group (p = 0.839). The changes in treadmill exercise time with treatment were insignificant and similar in the 2 groups (p = 0.938). C-reactive protein and interleukin-6 were both significantly reduced in the colchicine group (-5.1 mg/l and -4.8 pg/ml, respectively; p < 0.001 for both, compared with the control group).
conclusionsAccording to this prospective, randomized study, anti-inflammatory treatment with colchicine in patients with stable CHF, although effective in reducing inflammation biomarker levels, did not affect in any significant way patient functional status (in terms of New York Heart Association class and objective treadmill exercise tolerance) or the likelihood of death or hospital stay for heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.